肌萎缩性侧索硬化症相关的Cu,Zn-SOD

超氧化物歧化酶（superoxide dismutase,SOD）被称为生物体内自由基的清洁剂,其主要形式Cu,Zn-SOD称SOD1. SOD1突变体可引起致死性运动神经元疾病肌萎缩性侧索硬化症(ALS).但是,SOD1的毒性机理尚未完全清楚.本文概述了SOD1、Cu分子伴侣（copper chaperone for SOD1,CCS）的分子结构和CCS活化SOD1的机理,重点分析了突变体SOD1构象变化的原因及其在ALS中的可能致病机制的最新研究进展.     

肌萎缩侧索硬化症与肠道菌群关系研究进展

肌萎缩侧索硬化症(amyotrophic lateral sclerosis, ALS)是一种复杂的神经退行性疾病,目前尚无完全治愈的疗法。临床治疗皆以延缓病程,提高患者生活质量为主。“肠-肌轴调控”的概念提示,可通过调控肌肉萎缩患者肠道菌群来改善肌肉质量,这为临床提供新的治疗思路。通过基因测序发现ALS模型小鼠的肠道菌群组成和相对丰度与正常小鼠有显著差异。研究发现一些肠道细菌对ALS具有一定的调节作用。微生物群的靶向治疗也已成为全球研究热点。益生菌个体化匹配治疗可获得深入的个体化宿主数据和微生物组学数据,并确定相关的微生物标志物,从而实现益生菌的精准补充,这可能成为ALS临床治疗的新方向。     

清栓酶治疗肌萎缩侧索硬化症4例

清栓酶治疗肌萎缩侧索硬化症４例韩贞普何振朝贵州省凯里市４１８医院５５６０００我院内科用清栓酶治疗肌萎缩侧索硬化症４例,收到较满意的效果,现总结如下：１临床资料１．１一般资料：男性３例,女性１例,年龄４１岁～５７岁。病程１年～５年,４例均有典型临床表现...     

原发性侧索硬化症1例

1　临床资料　　患者 ,男 ,3 7岁。因左下肢乏力震颤 6个月 ,右下肢震颤 2 0多天入院。患者 6个月前开始无诱因出现左下肢乏力 ,伴该肢体不自主震颤 ,逐渐加重 ,穿鞋困难 ,行走时步态不稳 ,伴有腰胀感 ,睡眠时震颤消失。 2 0多天前开始右下肢亦出现震颤现象 ,但较左侧轻 ,且无明显乏力。病后肢体无麻木疼痛 ,亦无头痛、畏寒发热现象。入院查体 :体温 3 6 .5℃ ,血压 1 4.7/9.3 3 k Pa,神志清楚 ,表情自然 ,痉挛性步态 ,自动体位。两眼无斜视 ,两瞳孔等大等圆 ,对光反射灵敏。口角不偏。可鼓腮 ,吹口哨。颈似稍硬 ,脊柱四肢无畸形 ,四肢肌肉…     

不同行为学测试方法在家族性肌萎缩侧索硬化小鼠模型的比较

目的比较目前常用的5种行为学检测方法在家族性肌萎缩侧索硬化鼠模型研究中的作用。方法分为模型组(SOD1-G93A转基因鼠)和阴性对照组(同窝阴性对照)。使用5种行为学评价方法(一般状况评分、体重测定、转棒试验、抓力测定和步长分析)评价其行为学变化。结果 (1)一般状况评分:在第89天,模型组的一般状况评分开始下降。在第101天时,与对照组相比开始有统计学差异(P=0.000)。(2)体重测定:15周(第105天)时,模型组的体重开始下降,且与阴性对照组相比(P=0.026),开始有统计学差异。(3)转棒试验:11周(第77天)时,模型组的转棒时间开始下降。第13周(第91天)时,与阴性对照组相比开始有统计学差异(P=0.047)。(4)抓力测定:10周(第70天)时,模型组的后肢抓力开始下降。第13周(第91天)时,与阴性对照组相比开始有统计学差异(P=0.000)。(5)步长分析:第14周(第98天)后模型组的步长开始变短。15周(第105天)时与阴性对照组相比开始有统计学意义(P=0.000)。结论抓力测定优于其他行为学检测方法。     

肌萎缩侧索硬化患者SOD1基因突变检测及突变与临床表型的关系

应用PCR技术结合DNA直接测序方法对8例临床确诊为家族性肌萎缩侧索硬化(Familiar amyotrophic lateral sclerosis,FALS)家系的先证者进行铜锌超氧化物歧化酶基因(SOD1)的突变筛查,在3例先证者中检出2种SOD1基因突变,其中,2例携带了位于4号外显子的错义突变Cys111Tyr(c.332G>A),另1例携带了位于5号外显子的错义突变Gly147Asp(c.440G>A),这2种突变在中国ALS患者中属首次报道。该结果扩大了中国FALS患者的SOD1基因突变谱,对研究中国FALS患者SOD1基因突变特点和分布规律有一定帮助。分析携带这2个突变患者的临床特点,提示Cys111Tyr突变导致的临床表型相对温和,而Gly147Asp突变可导致病情进展较快。该结果有待在更多的病例中进行证实。     

3 例以延髓麻痹为首发表现的肌萎缩侧索硬化的病例报告

目的:探讨以延髓麻痹为首发症状的肌萎缩侧索硬化的临床特点。方法:报告3例以构音障碍等延髓麻痹症状起病的肌萎缩侧索硬化少见病例,结合文献复习,分析其临床特点。结果:在ALS患者中,以延髓麻痹为首发症状发生率相对较低,多见于老年人,最易表现为构音障碍,患者的生存期缩短,预后不良。结论:对于以延髓麻痹表现起病的ALS患者,要引起重视,及时针对延髓麻痹对症治疗,改善患者生活质量。     

肌萎缩侧索硬化脊髓器官型培养模型的建立

利用谷氨酸转运体抑制剂苏—羟天冬氨酸(THA)制备选择性运动神经元凋亡的肌萎缩侧索硬化(ALs)脊髓器官型培养模型。取出生后8天乳鼠腰段脊髓组织切成脊髓薄片,在培养液中分别加入不同浓度THA,用SMI—32免疫组化染色对脊髓腹角α运动神经元进行鉴定,calretinin免疫组化染色对背角中间神经元进行鉴定,测定培养液中谷氨酸(Glu)、乳酸脱氢酶(LDH)的含量,并与对照组比较。结果显示对照组α运动神经元数目恒定;THA引起培养液中剂量依赖性Glu、LDH含量增高和SMI—32阳性的α运动神经元数目减少,脊髓背角的中间神经元损伤相对较轻;100μmol／L THA组在体外培养4周后,细胞外Glu含量增高,SMI—32阳性的α运动神经元数目较对照组明显减少,背角的中间神经元数目无显著变化,可以制成ALS脊髓器官型培养模型。     

肌萎缩侧索硬化患者肌电图F波和束颤波的特点及其相关性*

目的:研究肌萎缩侧索硬化(ALS)患者肌电图检查中异常F波与束颤波的特点及其相关性。方法:收集2016年9月至2018年2月就诊于浙江大学医学院附属第二医院神经内科的54例ALS患者,进行常规肌电图检查和F波测定,记录216条正中神经、胫后神经的F波以及324块肌肉的束颤波相关参数,计算F波出现率、巨大F波、束颤波的出现率及其异常率,分析巨大F波、束颤波与病程的关系以及巨大F波和束颤波之间的关联性。结果:F波出现率的异常率88.89%,巨大F波出现率55.56%,束颤波出现率48.15%;有束颤波的病程与没有束颤波病程比较具有明显差异(P＜0.01),有巨大F波的病程与未出现巨大F波病程比较无明显差异(P＞0.05);上肢正中神经巨大F波出现与束颤波的出现无关联(P＞0.05),下肢胫后神经巨大F波出现与束颤波的出现比较具有相关性(P=0.05)。结论:以上肢为主的F波出现率异常、以下肢为主的巨大F波和束颤波的出现可作为ALS电生理诊断阳性指标。有束颤波或巨大F波时可考虑疾病相对较早,且有较好的神经再支配及代偿,进展相对较慢。     

稳定表达hSOD1^G93A基因的肌萎缩侧索硬化体外细胞培养模型的建立与鉴定

目的建立并鉴定稳定表达G93A型突变人超氧化物歧化酶（hSOD1^G93A）基因的肌萎缩侧索硬化体外细胞培养模型。方法利用活化的树突状聚合物将空质粒、hSOD1^WT、hSOD1^G93A基因转染入VSC4.1细胞内,G418抗性筛选,从而建立稳定的肌萎缩侧索硬化体外细胞模型。用免疫荧光技术检测VSC4.1细胞系运动神经元标志物。蛋白印迹实验鉴定hSOD1^WT蛋白、hSOD1^G93A蛋白的表达。MTT法检测细胞模型生长曲线。结果VSC4.1细胞分化前表达ClassⅢβ-Tubulin、MNR2,分化后表达ClassⅢβ-Tubulin、MNR2、NF200、MAP2等运动神经元标志物。VSC4.1-hSOD1^WT、VSC4.1-hSOD1^G93A细胞均过表达人来源的SOD1,而VSC4.1-mock则不表达。与VSC4.1-mock、VSC4.1-hSOD1^WT相比,VSC4.1-hSOD1^G93A生长缓慢,在48、72 h细胞活力均低于VSC4.1-mock（P=0.031,P=0.000）、VSC4.1-hSOD1^WT（P=0.001,P=0.000）,其余时间点无明显差异（P〉0.05）。结论成功建立稳定表达hSOD1^WT、hSOD1^G93A基因的VSC4.1细胞系,为进一步研究肌萎缩侧索硬化的发病与治疗奠定了良好的基础。     

Mitochondrial Degeneration in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that causes motor neuron degeneration, progressive skeletal muscle atrophy, paralysis, and death. To understand the mechanism of motor neuron degeneration, we have analyzed the clinical disease progression and the pathological changes in a transgenic mouse model for ALS. We found massive mitochondrial vacuolation at the onset of disease. By detailed morphological observations, we have determined that this mitochondrial vacuolation is developed from expansion of mitochondrial intermembrane space and extension of the outer membrane and involves peroxisomes. Lysosomes do not actively participate at all stages of this vacuolation. We conclude that this mitochondrial vacuolation is neither classical mitochondrial permeability transition nor autophagic vacuolation. Thus, this appears to be a new form of mitochondrial vacuolation and we term this as mitochondrial vacuolation by intermembrane space expansion or MVISE.     

Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis

1. Download high-res image (188KB)
2. Download full-size image

     

Protein Oxidative Damage in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis

Abstract: The Gly⁹³→Ala mutation in the Cu,Zn superoxide dismutase (Cu,Zn-SOD) gene (SOD1) found in some familial amyotrophic lateral sclerosis (FALS) patients has been shown to result in an aberrant increase in hydroxyl radical production by the mutant enzyme that may cause oxidative injury to spinal motor neurons. In the present study, we analyzed the extent of oxidative injury to lumbar and cervical spinal cord proteins in transgenic FALS mice that overexpress the SOD1 mutation [TgN(SOD1-G93A)G1H] in comparison with nontransgenic mice. Total protein oxidation was examined by spectrophotometric measurement of tissue protein carbonyl content by the dinitrophenylhydrazine (DNPH) assay. Four ages were investigated: 30 (pre-motor neuron pathology and clinical disease), 60 (after initiation of pathology, but pre-disease), 100 (～50% loss of motor neurons and function), and 120 (near complete hindlimb paralysis) days. Protein carbonyl content in 30-day-old TgN(SOD1-G93A)G1H mice was twice as high as the level found in age-matched nontransgenic mice. However, at 60 and 100 days of age, the levels were the same. Then, between 100 and 120 days of age, the levels in the TgN(SOD1-G93A)G1H mice increased dramatically (557%) compared with either the nontransgenic mice or transgenic animals that overexpress the wild-type human Cu,Zn-SOD [TgN(SOD1)N29]. The 100–120-day increase in spinal cord protein carbonyl levels was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoretic separation and western blot immunoassay, which enabled the identification of heavily oxidized individual proteins using a monoclonal antibody against DNPH-derivatized proteins. One of the more heavily oxidized protein bands (14 kDa) was identified by immunoprecipitation as largely Cu,Zn-SOD. Western blot comparison of the extent of Cu,Zn-SOD protein carbonylation revealed that the level in spinal cord samples from 120-day-old TgN(SOD1-G93A)G1H mice was significantly higher than that found in age-matched nontransgenic or TgN(SOD1)N29 mice. These results suggest that the increased hydroxyl radical production associated with the G93A SOD1 mutation and/or lipid peroxidation-derived radical species (peroxyl or alkoxyl) causes extensive protein oxidative injury and that the Cu,Zn-SOD itself is a key target, which may compromise its antioxidant function.     

Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis

1. Download : Download high-res image (267KB)
2. Download : Download full-size image

     

Tau Isoforms Expression in Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Tau is a protein involved in regulation of microtubule stability, axonal differentiation and transport. Alteration of retrograde transport may lead to motor neuron degeneration. Thus alternative mRNA splicing and expression of tau isoforms were studied in a transgenic mouse model harboring the human SOD1 G93A mutation. The studies were performed on cortex, hippocampus and spinal cord of 64- and 120-day-old animals (presymptomatic and symptomatic stage) and wild type controls. Exon 10 was found in all studied tissues. The 2N isoform containing exons 2 and 3 (+2+3) and the 1N (+2−3) predominated over the 0N (−2−3) in brain regions of the studied mice. The 2N expression was significantly lower in cortex and hippocampus of symptomatic animals compared to analogue control tissues. The decrease in 2N expression resulted in lower levels of total tau mRNA and tau protein. No changes in tau expression were observed in spinal cord of studied animals.     

Molecular Analyses of the Cu/Zn Superoxide Dismutase Gene in Patients with Familial Amyotrophic Lateral Sclerosis (ALS) in Japan

1. Amyotrophic lateral sclerosis (ALS) is a degenerative disorder characterized by selective damage to the neural system that mediates voluntary movement. Although the pathophysiologic process of ALS remains unknown, about 5 to 10% of cases are familial. According to genetic linkage studies, the familial ALS (FALS) gene has been mapped on chromosome 21 in some families and recent work identified some different missense mutations in the Cu/Zn superoxide dismutase gene in FALS families.2. We recently identified five mutations in six FALS families. The mutations identified in our FALS families are H46R, L84V, I104F, S134N, and V148I. The H46R mutation that locates in the active site of Cu/Zn SOD gene is associated with two Japanese families with very slow progression of ALS. On the other hand, the L84V mutation associated with a rapidly progressive loss of motor function with predominant lower motor neuron manifestations.3. In the family with the V148I, the phenotype of the patient varied very much among the affected members. One case had weakness of the lower extremities at first and died without bulbar paresis. The second case first noticed wasting of the upper limbs with bulbar symptoms, but the third had weakness of upper extremities without developing dysarthria nor dysphagia until death. These mutations account for 50% of all FALS families screened, although Cu/Zn SOD gene mutations are responsible for less than about 13–21% in the Western population.4. Our results indicate that the progression of disease with mutations of Cu/Zn SOD is well correlated with each mutation. The exact mechanism by which the abnormal Cu/Zn SOD molecules selectively affect the function of motor neurons is still unknown.     

MAP4K4 Activation Mediates Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis

1. Download high-res image (139KB)
2. Download full-size image

     

Anti-Sulfoglucuronosyl Paragloboside Antibody: A Potential Serologic Marker of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive degeneration of upper and lower motor neurons. Although the etiology of ALS is obscure, genetic studies of familiar ALS suggest a multifactorial etiology for this condition. Similarly, there probably are multiple causes for sporadic ALS. Autoimmune-mediated motor neuron dysfunction is one proposed etiology for sporadic ALS. In the present study, anti-glycolipid antibodies including GM1, GD1b, GD3, and sulfoglucuronosyl paragloboside (SGPG) were investigated in the sera of a large number of patient samples, including 113 ALS patients and 50 healthy controls, by means of enzyme-linked immunosorbent assay with affinity parametric complex criterion evaluation and thin-layer chromatography immunooverlay (immuno-TLC). Anti-SGPG antibodies were found in the sera of 13.3% ALS patients (15 out of 113). The highest titer reached 1:1600. The presence of anti-SGPG antibodies in the serum samples was also confirmed by immuno-TLC. Importantly, a multiple logistic regression analysis showed that the presence of anti-SGPG antibody was positively correlated with age (p < .01) and negatively correlated with ALS Functional Rating Scale score (p < .05). Moreover, the localization of SGPG-immunoreactivity on the motor neurons of rat spinal cord and a mouse motor neuronal cell line, NSC-34 was observed by an immunofluorescence method. These data suggest that SGPG could represent a specific pathogenic antigen in those ALS patients. The presence of anti-SGPG antibodies in the serum of ALS patients should represent a diagnostic biomarker of ALS, and it could reflect the severity of the disease.